title: Diltiazem-associated photodistributed hyperpigmentation: report of two Japanese cases and published work review.
abstract: Scherschum et al. proposed diltiazem-associated photodistributed hyperpigmentation as a novel type of drug-induced photosensitive lichenoid eruption. The characteristic clinical features were slate-gray reticulated hyperpigmentation on sun-exposed areas, while lichenoid dermatitis with prominent pigmentary incontinence was noted histologically. Although the clinical and histological features were similar to those of lichen planus pigmentosus, the histological features did not show either compact hyperkeratosis or wedge-shaped hypergranulosis, which are typical histological features of lichen planus. We describe two Japanese cases of diltiazem-associated photodistributed hyperpigmentation, who were successfully treated with topical tacrolimus, and review the published work.
authors.affiliation: Department of Dermatology, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan. ykubo@clin.med.tokushima-u.ac.jp
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Kubo
authors.forename: Daisuke
authors.initials: D
authors.lastname: Fukumoto
authors.forename: Takeshi
authors.initials: T
authors.lastname: Ishigami
authors.forename: Yasutoshi
authors.initials: Y
authors.lastname: Hida
authors.forename: Seiji
authors.initials: S
authors.lastname: Arase
mesh_terms: D000369:Aged, 80 and over; D044466:Asian People; D002121:Calcium Channel Blockers / Q000009:adverse effects* / Q000627:therapeutic use; D004110:Diltiazem / Q000009:adverse effects* / Q000627:therapeutic use; D003875:Drug Eruptions / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D005260:Female; D006801:Humans; D017495:Hyperpigmentation / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D007564:Japan; D010787:Photosensitivity Disorders / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D016559:Tacrolimus / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D002121:Calcium Channel Blockers; D004110:Diltiazem; D016559:Tacrolimus